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Abstract
Background: Opportunistically nosocomial infections in hospitalized patients are often related to Clostridium difficile
infections (CDI) due to disruption of the intestinal micro-flora by antibiotic therapies during hospitalization.
Clostridial exotoxins A and B (TcdA and TcdB) specifically bind to unknown glycoprotein(s) in the host intestine,
disrupt the intestinal barrier leading to acute inflammation and diarrhea. The C-terminal receptor binding domain
of TcdA (A-rRBD) has been shown to elicit antibody responses that neutralize TcdA toxicity in Vero cell cytotoxicity
assays, but not effectively protect hamsters against a lethal dose challenge of C. difficile spores. To develop an
effective recombinant subunit vaccine against CDI, A-rRBD was lipidated (rlipoA-RBD) as a rational design to contain
an intrinsic adjuvant, a toll-like receptor 2 agonist and expressed in Escherichia coli.
Results: The purified rlipoA-RBD was characterized immunologically and found to have the following properties:
(a) mice, hamsters and rabbits vaccinated with 3 μg of rlipoA-RBD produced strong antibody responses that
neutralized TcdA toxicity in Vero cell cytotoxicity assays; furthermore, the neutralization titer was comparable to
those obtained from antisera immunized either with 10 μg of TcdA toxoid or 30 μg of A-rRBD; (b) rlipoA-RBD
elicited immune responses and protected mice from TcdA challenge, but offered insignificant protection (10 to
20 %) against C. difficile spores challenge in hamster models; (c) only rlipoA-RBD formulated with B-rRBD
consistently confers protection (90 to 100 %) in the hamster challenge model; and (d) rlipoA-RBD was found to be
10-fold more potent than A-rRBD as an adjuvant to enhancing immune responses against a poor antigen such
as ovalbumin.
Conclusion: These results indicate that rlipoA-RBD formulated with B-rRBD could be an excellent vaccine candidate
for preclinical studies and future clinical trials.
Keywords: Antibiotic-associated pseudo-membranous colitis, C. difficile toxins, Receptor binding domain,
Lipoprotein, Toll-like receptor agonist, Adjuvant
Background
Clostridium difficile has become an emerging infectious
pathogen that is responsible for opportunistic infections in
hospitals worldwide and is the main cause of antibiotic-
associated pseudo-membranous colitis in humans [1–3].
Moreover, the finding of a hyper-virulent and antibiotic-
resistant epidemic strain, BI/NAP1/027 in developed
countries, poses a major challenge for preventing
C. difficile infections (CDIs) [4–6]. The pathogenicity of
C. difficile is largely mediated by two clostridial toxins,
toxin A and toxin B (TcdA and TcdB), that are secreted in
the gastrointestinal environment of infected hosts and dis-
rupt the epithelial cell barriers in the small intestine [7].
Both toxins consist of holotoxins with multi-functional
domains that mediate C. difficile pathogenesis. The mech-
anism underlying TcdA and TcdB toxicity involves three
steps: (a) binding to unidentified receptor protein(s) on the
surface of intestinal epithelium and internalization through
its C-terminal receptor binding domain, (b) auto-cleavage
and translocation of the N-terminal glucosyltransferase
domain to the cytosol from the endosomal membrane;
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and (c) the N-terminal enzymatic region that inactivates
the Rho GTPase family by glycosylation [7, 8].
Interestingly, TcdA-specific antibodies in patient sera
were found to positively correlate with the prevention of
CDAD recurrence [9–12]. Therefore, passive immunization
with anti-toxin antibodies has been shown to confer pro-
tection against CDI in animal models and TcdA-specific
monoclonal antibodies are currently being tested in clinical
trials [13–15]. In addition, different C. difficile vaccine
strategies are being evaluated; the most advanced being
vaccination with formalin-inactivated toxins [16–19].
Immunization with the receptor binding domain (RBD) of
C. difficile toxins as an antigen formulated with different
adjuvants has been shown to elicit toxin-neutralizing anti-
body responses and protect mice from toxin or bacteria
challenges [20–26]. TcdA RBD (A-rRBD) has a molecular
size around 100 kDa and is composed of 32–38 homolo-
gous repetitive peptides which contain 7 potential lectin-
like receptor-binding sites for binding to the synthetic
oligosaccharide, Galα1-3Galβ1-4GlcNAc that is often
found in glycoproteins [8, 20, 27–29]. The specific roles
and functions of these 7 putative binding regions are un-
clear. In our previous study [30], a recombinant A-rRBD
based on the consensus sequence of TcdA identified from
different C. difficile strains obtained from the NCBI pro-
tein database and three truncated fragments of RBD corre-
sponding to the N-terminal (residues 1–411), middle
(residues 296–701), and C-terminal parts (residues
524–911) (F1, F2 and F3, respectively) were designed
and expressed in E. coli. The purified A-rRBD and its
fragments were characterized biologically and found to
have the following properties: (a) A-rRBD and the trun-
cated fragments are capable of binding to the cell sur-
face and internalizing into both Vero and Caco-2 cells; (b)
A-rRBD, F3 and F2 show various level of hemagglutinin
(HA) activity, but F1 has no HA activity; and (c) A-rRBD
and the truncated fragments can act as a toll-like receptor
agonist activating dendritic cell maturation, but F3 is the
most potent. The results indicated that F1, F2 and F3 have
similar repetitive amino acid sequences and putative
oligosaccharide-binding domains, but they do not express
the same level of biological properties. In another study
[31], a TcdB RBD derived from C. difficile strain VPI10463
which has >95 % amino acid sequence identity to BI/
NAP1/027 hyper-virulent strains was designed and
expressed in E. coli. Recombinant TcdB RBD (B-rRBD)
was purified, characterized biologically and immunologic-
ally, and found to have the following properties: (a)
capable of binding to the cell surface of both Vero and
Caco-2 cells and entering into the cytosol; (b) showing no
hemagglutinin activity (HA); (c) functioning as a toll-like
receptor agonist activating dendritic cell maturation; (d) in
the absence of adjuvant, eliciting anti-TcdB neutralizing
antibody responses that could weakly cross-neutralize
TcdA; and (e) inducing partial protection against a lethal
dose of C. difficile spores in the hamsters challenge model.
To develop an effective recombinant subunit vaccine
against CDI, in this study, A-rRBD was lipidated (rlipoA-
RBD) as a rational design to contain an intrinsic adjuvant,
toll-like receptor 2 agonist and expressed in E. coli. The
purified rlipoA-RBD was further characterized immuno-
logically and tested to determine whether it could be a
highly efficacious vaccine candidate against CDAD, or if it
required formulation with B-rRBD and adjuvant.
Methods
Ethics statement
All experiments were conducted in accordance with the
guidelines of the Laboratory Animal Center of National
Health Research Institutes (NHRI). Animal use protocols
have been reviewed and approved by the Institutional
Animal Care and Use Committee of National Health
Research Institutes (Approved protocol No. NHRI-IACU
C-100053-A).
Production of A-rRBD and B-rRBD
The purification of A-rRBD and B-rRBD expressed in E.
coli JM109 (DE3) strain have been previously described
[30, 31]. All purification steps were analyzed by 8 % SDS-
PAGE. The residual endotoxin was determined using the
Limulus amoebocyte lysate (LAL) assay (Associates of
Cape Cod, Inc., Cape Cod, MA).
Construction, expression and purification of rlipoA-RBD
Construction of plasmid containing rlipoA-RBD was
cloned into the pET-22b (+) vector using Bam HI and
Xho I sites as previously described [32]. These constructs
were expressed in the E. coli C43 (DE3) strain. In brief, the
3’-end of A-rRBD was fused with the sequence containing
a polyhistidine tag and XhoI restriction enzyme site [30].
The 5’ terminus was fused to E. coli. lipidated signal se-
quence by BamHI restriction enzyme site [32]. The 5’-end
of lipid leader sequence also contained a NdeI restriction
enzyme site. Finally, A-rRBD nucleotide sequence posses-
sing 5’-lipid leader sequence and 3’ polyhistidine sequence
containing NdeI and XhoI sites, respectively, was cloned
into pET-22b(+) vector (Novagen, Darmstadt, Germany)
by the NdeI and XhoI restriction enzyme sites. This pET-
22b(+)_rlipoA-RBD construct was transformed into E. coli
C43 (DE3) (Imaxio; Saint-Beauzire, France) for rlipoA-
RBD expression. rlipoA-RBD was over-expressed in 5
liters of LB Broth containing 100 μg/ml ampicillin by E.
coli C43 (DE3) (Imaxio; Saint-Beauzire, France). Once
OD600nm of bacteria culture achieved approximately 0.5,
1 mM isopropyl-β-D- thiogalacto-pyranoside (IPTG) was
added into the culture medium to incubate at 20 °C for
16 h. Bacteria were harvested by centrifugation and stored
at −20 °C before lysis. Bacterial pellet was suspended in
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lysis buffer (50 mM Tris-Cl, pH8.0 containing 500 mM
NaCl) and disrupted physically by French Press (Constant
System, Daventry, UK) at 27 Kpsi. Cell lysate was pelleted
and extracted twice with 50 mM Tris-Cl, pH8.0 contain-
ing 0.5 % Triton X-100. The crude-extracted solution was
purified by two step affinity chromatograph. First, nickel
resin was used to separate any impurities. The eluent was
dialyzed to remove imidazol and applied to an immobi-
lized metal affinity chromatography (IMAC) (GE Health-
care, Uppsala, Sweden) charged with copper ion for LPS
removal. All purification steps were performed at 4 °C and
analyzed by 8 % SDS-PAGE. Affinity chromatography was
performed according to manufacturer’s instruction. The
residual endotoxin was determined by LAL assay (Associ-
ates of Cape Cod, Inc., Cape Cod, MA). The eluent was
dialyzed in a 30 kDa cut-off dialysis bag against phos-
phate buffered saline (PBS), pH 7.2 containing 15 %
glycerol, and stored at −80 °C. In all experiments, pro-
tein quantification was determined by BCA Protein
Assay Kit (Thermo Pierce). The 104-kDa rlipoA-RBD
was separated by 8 % SDS-PAGE. Samples separated in
the gel were transferred onto PVDF membrane (GE).
PVDF membrane was blocked with 5 % nonfat dry milk
(w/v) in PBS for 1 h. To specifically identify rlipoA-
RBD, the membrane was inoculated with anti-his tag
(AbD Serotec; Kidlington, UK) or anti-TcdA antibodies
(Clone PCG-4; GenTax, Taiwan) in PBS containing 1 %
nonfat dry milk (w/v) for 1 h. After washing twice with
PBST (PBS containing 0.05 % Tween 20), HRP-conjuga
ted secondary antibodies in PBS containing 1 % milk
was added and incubated for 1 h. Membrane was
washed twice with PBST and developed using Luminata
Crescendo substrate according to manufacturer’s instruc-
tion (Millipore, Billerica, MA). The lipid moiety of rlipoA-
RBD was also analyzed using mass spectroscopy [32].
Surface markers and cytokines analyses for DC
maturation
Analysis of DC maturation was performed in vitro as
previously described [30, 33]. C57BL/6 mice were pur-
chased from National Animal Center in Taiwan and
held at the Animal Center of the NHRI. In brief, bone
marrow-derived DCs (BMDCs) were collected from the
tibiae of 6 to 8-week old C57BL/6 females. Bone mar-
row cells were isolated by vigorous washing with LCM
(RPMI 1640 containing 1 % antibiotics with penicillin
and streptomycin, 10 % heat-inactivated FBS, 50 μM β-
mercaptoethanol, and 50 mM HEPES) and treated with
lysis buffer to remove erythrocytes. BMDC were re-
suspended at 2 × 106 cells per mL in LCM and treated
with a final 20 ng/mL of recombinant granulocyte
macrophage colony stimulating factor (MoGM-CSF)
(Peprotech, Rocky Hill, NJ) on days 0 and 3. An aliquot
of suspended BMDCs equivalent to 1 × 106 cells/mL
was seeded into 24-well plates on day 6. Different con-
centrations of rlipoA-RBD with or without 10 ng of
polymyxin B were added into the wells. LPS (1000 EU,
Sigma-Aldrich) served as the control. After 16 to 18 h
incubation at 37 °C, BMDCs were analyzed by flow cy-
tometry (FACSCalibur, BD Biosciences, Franklin Lakes,
NJ) to evaluate the up-regulation of cell surface
markers. In order to exclude immature DCs, which rep-
resent 50 % of the total cell population, the CD11c+ cell
population was gated for surface marker staining with
specific monoclonal antibodies to CD-40, CD-80, CD-
86, and MHC-II. In addition, cell culture supernatants
were collected for cytokine expression. Cytokines such as
IL-6, IL-12p40 and TNF-α were determined using specific
cytokine kits purchased from eBioscience (San Diego,
CA). All experiments were performed at least three times.
To eliminate the DC activation by rlipoA-RBD is not
mouse strain specific, similar experiments were performed
with BMDCs obtained from BALB/c mice.
Antigen immunogenicity in the mouse model
BALB/c mice were purchased from the National Animal
Center in Taiwan and held at the Animal Center of the
NHRI. Groups of mice (6 BALB/c mice per group) were
vaccinated with three intramuscular injections of various
amounts of either (a) rlipoA-RBD (3, 10 or 30 μg) or (b)
A-rRBD (3, 10 or 30 μg) every two weeks. Before each
immunization (week 0, week 2, week 4 and week 6),
mice were bled by tail vein to collect sera that were
stored at −20 °C before used in anti-RBD antibody titer
determination. To study the adjuvant effect of rlipoA-
RBD, individual groups of 4 BALB/c mice were immu-
nized intramuscularly with 2 μg of ovalbumin (OVA)
(Sigma-Aldrich) formulated either with various amounts
of rlipoA-RBD (0.3, or 3 μg), or 10 μg of A-rRBD or
alum (Sigma-Aldrich). Animals that received 2 μg of
OVA alone served as the control. The mice were given
three immunizations at two week intervals and bled
before each injection. Sera were collected and stored at
−20 °C for anti-OVA antibody titer measurement using
OVA-specific ELISA as described below.
Rabbit immunogenicity study
New Zealand white (NZW) rabbits with 1.6–to 2.0- kg
body weight were purchased from Livestock Research
Institute in Taiwan and held at the Animal Center of the
NHRI for experiments. Groups of two NZW rabbits
were intramuscularly vaccinated with 10 μg of either
rlipoA-RBD or A-rRBD formulated with alum three
times, 14 days apart. Before each immunization (week 0,
week 2, week 4 and week 6), rabbits were bled via the
central ear artery. Sera were collected and stored
at −20 °C for further analyses.
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Antigen-specific ELISA
ELISA plate wells were coated either with 100 ng of
A-rRBD or OVA at 4 °C overnight, then blocked with
5 % nonfat dry milk (w/v) in PBS. Mouse antisera 2-fold
serially diluted with PBS containing 1 % BSA (Calbiochem,
Darmstadt, Germany) were added to the wells followed by
incubation at room temperature (RT) for 2 h. After wash-
ing with 3 × PBST, either anti-IgG isotypes (Invitrogen,
Carlsbad, CA.) or anti-IgA (Invitrogen, Carlsbad, CA)
HRP-conjugated IgG (KPL, Gaithersburg, MD) specific
antibodies diluted in PBS containing 1 % BSA were added
to the wells and incubated at RT for 1 h. After washing
with 3 × PBST, the plates were treated with TMB peroxid-
ase substrate (KPL) at room temperature in the dark for
20 min. To determine anti-A-rRBD or anti-OVA titer,
OD450nm absorbance was measured using a spectro-
photometer (Spectra max M2, Molecular Devices,
Sunnyvale, CA).
Anti-toxin neutralization assay
The anti-TcdA neutralization assay was performed accord-
ing to the protocol previously described by Huang et al.
[31]. Briefly, Vero cells (2 × 104 per well) were seeded into
96-well plates containing VP-SFM culture medium
(Invitrogen, Carlsbad, CA) and 4 mM glutamine at 37 °C,
and allowed to grow to confluent. Mouse sera from mice
immunized either with rlipoA-RBD or A-rRBD or B-rRBD
were serially diluted two-fold with fresh VP-SFM and
mixed with an equal volume of either 20 ng/mL TcdA or
40 pg/mL of TcdB (The Native Antigen Company Ltd,
Oxfordshire, UK) and incubated at room temperature for
1 h. The mixture was added to the 96-well plates contain-
ing Vero cells and incubated at 37 °C for 24 h. Anti-TcdA
neutralization titers were calculated as the highest serum
dilution which could protect 50 % of cells from rounding
due to toxin cytotoxicity. Cellular toxicity was recorded
using a microscope equipped with a camera.
TcdA challenge in the mouse model
A lethal TcdA challenge mouse model was established to
assess the efficacy of anti-RBD immune responses in vivo
using the protocol previously described by Seregin et al.
[21]. Briefly, groups of BALB/c mice (10 mice per
group) were immunized intramuscularly with either
PBS or three dosages of various amounts of immuno-
gens (rlipoA-RBD (0.3 or 3 μg), A-rRBD (0.3 or 3 μg)
or B-rRBD (30 μg)) without adjuvant at days 0, 14, and
28. After three immunizations, mice were challenged
with 150 ng of TcdA (5 × Lethal Dose (LD50)), by intra-
peritoneal injection on day 35 and monitored for
14 days. The mice were observed twice daily during the
first 3 days.
Preparation of C. difficile spores and hamster
challenge model
The protocol for preparation of C. difficile spores was
modified from the method previously reported by Lyras
et al., [34]. Briefly, C. difficile strains VPI10463 were
streaked on 10 anaerobic blood agar plates and grown
anaerobically at 37 °C to induce sporulation at around
the 5th or 6th day. The cells were harvested with dispos-
able loops and washed in 10 mL PBS, and heat-shocked
at 56 °C for 30 min to kill surviving vegetative cells. The
spores were collected by low-speed centrifugation and
resuspended in DMEM, aliquoted and frozen at −80 °C.
The frozen spores were then quantified before use by
plating ten-fold serial dilutions of the spores onto
Taurocholatefructose-agar (TFA) plates which were pre-
pared with agar plus taurocholate-cefoxitin- cycloserine
fructose-agar (TCCFA) without cycloserine and cefoxi-
tin. Hamster challenge model was performed as follows.
Six hamsters per group (6 weeks old and weighed
100–130 g) were purchased from National Animal
Center in Taiwan and held at the Animal Center of the
NHRI. Groups of hamsters were vaccinated with three
intramuscular injections of either (a) rlipoA-RBD
(10 μg) alone, (b) A-rRBD (10 μg) alone, (c) B-rRBD
(10 μg) alone, (d) rlipoA-RBD (10 μg) + B-rRBD
(10 μg), A-rRBD (10 μg) + B-rRBD (10 μg) formulated
with (e) 300 μg of aluminum phosphate (alum) or (f )
10 μg of Pam3CSK4 (InvivoGen, San Diego, CA) every
two weeks. Before each immunization, hamster blood
sera were carefully collected by the heart puncture and
stored at −20 °C before used in anti-RBD antibody titer
determination. After three immunizations as described
above, hamsters were given clindamycin orogastrically
(30 mg/kg) to render them susceptible to C. difficile
infection (day 0). On day-5 post clindamycin treatment,
hamsters in each group were gastrically inoculated with
100 cell forming unit (CFU) of C. difficile spores, and
monitored twice daily for 5 days and then daily
thereafter. Animal bedding was changed and faecal
pellets were collected every two days. Specimens were
inoculated onto selective TCCFA plates and incubated
anaerobically at 37 °C to determine if they were
colonized with C. difficile. Faecal pellets were collected
every two days for 12 days, then weekly until the study
terminated (at least 14 days). Each hamster group was
assessed for C. difficile colonization and survival rate.
Statistical analysis
Data was expressed using Prism 5 version 5.01 (GraphPad
Software, Inc.). Antibody titer was displayed as means ±
SEM from the experiments. Statistical difference was
analyzed using a two-tailed students’ t test by compari-
son of the means obtained in each treatment with the
control group.
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Results and discussion
Production of rlipoA-RBD
We have previously reported that both A-rRBD and B-
rRBD at 0.8 −1 μM have strong abilities to up-regulate
cell surface marker expression and cytokine secretion
from BMDCs [30, 31]. To enhance the effectiveness of
A-rRBD as a recombinant subunit vaccine candidate
against CDI, A-rRBD was rationally designed and lipidated
(rlipoA-RBD) to contain a toll-like receptor 2 agonist (in-
trinsic adjuvant) [32]. Construction of plasmid containing
rlipoA-RBD was cloned into the pET-22b(+) vector as
described in the Materials and Methods, and the construct
was successfully expressed in E. coli C43 (DE3) strain.
After the first single-step purification using Ni-affinity
chromatography, purified rlipoA-RBD with expected
molecular weight closed 100 kDa (>85 % purity) was ob-
tained and its purity confirmed by SDS-PAGE (Fig. 1a,
lanes 3 & 4). Most of the E. coli proteins and endotoxin
(LPS) were successfully removed by binding the rlipoA-
RBD preparation to the second IMAC-affinity column
and washing with PBS containing 0.1 % Triton-X100.
The purity of eluted rlipoA-RBD was confirmed by
SDS-PAGE (Fig. 1a, lane 5) and the western blot ana-
lysis using a TcdA-specific monoclonal antibody (Fig. 1b,
lane7). Trace amounts of rlipoA-RBD degradation frag-
ments were also detected using TcdA-specific antibody
(Fig. 1b). These degradation products are likely the
result of proteolytic digestion during the purification
process. The residual LPS in the purified rlipoA-RBD
were found to be below 30 EU per mL based on the
Limulus assay. In any event, at least 5−10 mg of highly
purified rlipoA-RBD was easily obtained from 1 l of
bacterial culture.
The lipid moiety of rlipoA-RBD was identified using
mass spectroscopy analysis [32]. The purified rlipoA-
RBD was digested with trypsin and the tryptic fragments
were analyzed using MALDI-TOF. Typical groups of
ion mass peaks which exhibit the post-translational
modification signature of recombinant lipoprotein, con-
tain three peaks with m/z values of 1452, 1466, and
1480 as shown in Fig. 2. The mass differences between
these peaks are 14 amu and the pattern of isotopes in
each group is exactly identical to that previous report
[32]. The circular dichroism (CD) secondary structure
analysis of rlipoA-RBD was also performed and found
that rlipoA-RBD had correctly folded to form β-sheet
structure similar to A-rRBD (>43 %) [30]. This result is
consistent with other reports that RBD forms stable
folded β-solenoid secondary structures independently
of other functional domains in the TcdA [30, 31].
Although a simple and rapid method for producing
rlipoA-RBD with high purity was successfully developed,
rlipoA-RBD was found to be unstable and showed a loss
in biological function during the freeze-thaw process. The
best condition for preserving rlipoA-RBD integrity was to
store the protein at 1 mg/mL in PBS containing 10 % (v/v)
of glycerol at −80 °C.
Dendritic cell maturation triggered by rlipoA-RBD
rlipoA-RBD was tested for its ability to promote the
maturation of DC. BMDCs from C57BL/6 mice were
treated with increasing amounts (0.2 to 2 μM) of
rlipoA-RBD, cell surface biomarkers associated with
DC maturation (CD40, CD80, CD86, and MHC-II) and
the secretion of pro-inflammatory cytokines (IL-6, IL-12,
and TNF-α) were examined using FACS analysis and
cytokine-specific ELISA, respectively. In order to preclude
the interference of LPS contamination, even though
rlipoA-RBD samples used in the current studies had very
little LPS contamination (0.03 EU/μg of protein), poly-
myxin B was added to DC samples to prevent activation
by LPS through the Toll-like receptor 4 pathways. It was
found that surface biomarkers of DC maturation were up-
regulated and that the production of pro-inflammatory
cytokines (IL-6, IL-12, and TNF-α) increased in a dose-
dependent manner (data not shown). A 0.5 μM of rlipoA-
RBD in the final assay solution was selected to perform
subsequent experiments and compare with the DC activa-
tion obtained from 0.5 μM of A-rRBD. Both the bio-
marker up-regulation (CD80, CD86 and MHC II) of DC
maturation and the production of pro-inflammatory
Fig. 1 The expression and purification of rlipoA-RBD. The expression
and the purity of rlipoA-RBD were confirmed by SDS-PAGE (a) and
western blot with TcdA-specific monoclonal antibody (b). The
purification of rlipoA-RBD as shown in panel a, lanes 2 to 4 were
crude extract loaded on the first Ni-affinity column, eluent of 200
and 500 mM imidazole, respectively. The purity of rlipoA-RBD
obtained from IMAC were confirmed by SDS-PAGE (panel a, lane 5)
and western blot with TcdA-specific monoclonal antibody (panel b,
lane 7). The first lane in each panel was the molecular markers
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cytokines (IL-12, and TNF-α) were detected significantly
higher in the rlipoA-RBD-treated BMDCs than those
obtained with A-rRBD (Fig. 3 & Fig. 4). No difference is
repeatedly observed for IL-6 that is a surprise. The
current results nevertheless strongly indicate that the
intrinsic adjuvant properties of rlipoA-RBD are signifi-
cantly (p < 0.05) more potent than A-rRBD. As observed
DC biomarker activation in Fig. 3, there are differences
between polymyxin B treated and non-treated sample
but these differences are not significant. In contrast, the
results in the production of the pro-inflammatory cyto-
kines were not influenced by minor LPS contamination
as there was no significant difference between poly-
myxin B treated and non-treated samples as shown in
Fig. 4. However, when both rlipoA-RBD samples and
LPS were boiled and tested for their biological func-
tions, boiling did not affect LPS-induced DC activation
but fully abolished rlipoA-RBD DC-activation ability
(data not shown). Overall, this clearly demonstrates
that DC activation is mediated by rlipoA-RBD. To
eliminate the DC activation by rlipoA-RBD is not
mouse strain specific, similar results were obtained
when BMDCs from BALB/c mice were examined for
cell surface biomarkers associated with DC maturation
and the secretion of pro-inflammatory cytokines using
FACS analysis and cytokine-specific ELISA (data not
shown). The results are consistent with our previous
reports [30–32].
Adjuvant property of rlipoA-RBD
To investigate whether rlipoA-RBD could provide an adju-
vant effect and enhance immune responses against poor
immunogens such as ovalbumin (OVA), mouse immuno-
genicity studies were performed using OVA (2 μg) formu-
lated with rlipoA-RBD (3 μg). A ten-fold increase in mouse
anti-OVA IgG titers (>104) was observed by formulating
OVA with rlipoA-RBD as compared to those obtained with
OVA alone (Fig. 5). To further investigate the adjuvant
activity of rlipoA-RBD, mouse immunogenicity studies
were repeated with OVA formulated with either 0.3 or
3 μg of rlipoA-RBD, 10 μg of A-rRBD, or alum (300 μg).
Interestingly, even a dose as low as 0.3 μg of rlipoA-RBD
exhibited a 10-fold increase in OVA-specific IgG titers
over those obtained with OVA alone (Fig. 5). The increase
in anti-OVA responses was shown to be statistically sig-
nificant (p < 0.001). There was no significant difference in
the immunogenicity of OVA formulated in rlipoA-RBD or
alum, but a significant difference was observed in the anti-
OVA IgG antibody responses elicited by rlipoA-RBD and
A-rRBD (p < 0.01) (Fig. 5). Again, these results indicate
that rlipoA-RBD provides stronger adjuvant activities and
enhancing immune responses against weak immunogens
compared to A-rRBD.
Mouse immunogenicity of rlipoA-RBD
Our previous studies [30, 31] had indicated that A-rRBD
(10 μg) and B-rRBD (10 μg) alone without adjuvant could
Fig. 2 MALDI-TOF analysis of tryptic digested lipopeptide fragments of rlipoA-RBD. The N-ternminal tryptic digested fragments were analyzed by
MLADI-TOF using the procedure described in previous report [32]
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elicit toxin-specific neutralizing antibody responses in
both mouse and rabbit models. To assess the immunogen-
icity of rlipoA-RBD, groups of mice (6 BALB/c mice per
group) were vaccinated with various amounts of rlipoA-
RBD. Analyses of mouse antisera from each immunization
using RBD-specific ELISA revealed that three doses of
3 μg of rlipoA-RBD already induced very strong anti-RBD
IgG antibody response (Fig. 6). The results shown in Fig. 6
also indicate that rlipoA-RBD is more immunogenic than
A-rRBD as rlipoA-RBD (2 x 3 μg) elicited stronger anti-
rRBD IgG antibodies (titer >105 at Week 4) than those im-
munized with 2 x 30 μg of A-rRBD (p < 0.01). Moreover,
antisera from mice vaccinated with 3 μg of rlipoA-RBD
both IgG1 and IgG2 isotypes antibody responses were ob-
served (data not shown). Post 6 week (after 3 doses) vac-
cination, anti-A-rRBD IgG antibody titers (~3 × 105)
elicited by 3 μg of rlipoA-RBD were not different from
those obtained with either 3 × 30 μg of A-rRBD or 3 ×
10 μg of TcdA toxoid (Table 1). Mouse antisera ob-
tained from mice vaccinated with 2 doses of 3 μg of
rlipoA-RBD was capable of inducing >105 anti-RBD IgG
titer (Fig. 6) which strongly supports rlipoA-RBD as a
good vaccine candidate.
Rabbit immunogenicity of rlipoA-RBD
To avoid animal-specific immune responses and further
assess the immunological properties of rlipoA-RBD,
rabbit immunogenicity was performed. Groups of 2 rab-
bits were vaccinated either with 10 μg of A-rRBD,
rlipoA-RBD or TcdA toxoid. The results indicated that
rlipoA-RBD is also highly immunogenic in rabbits since
2 × 10 μg (2 doses) of rlipoA-RBD alone produced anti-A-
rRBD IgG antibodies with an average titer >105, that was
comparable to antisera from rabbits vaccinated 3 times
Fig. 3 Up-regulation of surface biomarkers of BMDC by rlipoA-RBD. BMDC from C57BL/6 was collected and treated with GM-CSF on days 0 and 3.
A-rRBD and rlipoA-RBD were treated on day 6 for 18 h, then DC were collected to analyze their surface markers, including CD-40 (a), CD-86 (b),
CD-80 (c), and MHC-II (d) by flow cytometry. All groups were divided into polymyxin B (PMB) treated (black-net bar) or without (white bar) to
validate insignificant LPS contamination. All surface marker signaling was normalized by calculating the ratio of mean fluorescence intensity (MFI)
between medium control and treatments. The experiments had been performed at least three times
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with A-rRBD (data not shown). Rabbit anti-rRBD IgG
antibody responses elicited by 3 × 10 μg of rlipoA-RBD
were higher than those obtained with either 3 × 10 μg of
A-rRBD alone or 3 × 10 μg of TcdA toxoid (Table 1).
These results clearly indicate that 10 μg of rlipoA-RBD is
enough to induce strong anti-rRBD IgG antibody re-
sponses in rabbits.
Functional roles of anti-A-rRBD sera elicited by rlipoA-RBD
To determine whether mouse and rabbit anti-A-rRBD
antibodies elicited by rlipoA-RBD could functionally
neutralize the cytotoxicity of C. difficile TcdA and TcdB,
both mouse and rabbit antisera were tested in a Vero cell
cytotoxicity assay as described in Materials and
Methods. As shown in Table 1, antisera from both mice
and rabbits immunized with 3 x 10 μg of rlipoA-RBD
were capable of preventing 50 % of cell death resulting
from TcdA cytotoxicity at 1/512 dilution. This was not
significantly better than the results obtained from antisera
of animals immunized with 3 x 10 μg of A-rRBD (1/256).
However, the neutralization titers (1/512) obtained from
mice immunized 3 × 3 μg of rlipoA-RBD were found to be
significantly higher (p < 0.01) as compared to those ob-
tained from 3 × 3 μg of A-rRBD alone (1/32) (Table 1).
Anti-toxin neutralization titer obtained from mouse
sera with 30 μg of rlipoA-RBD was significantly higher
(p < 0.01) than those elicited either by 30 μg of A-rRBD
alone or 10 μg of TcdA toxoid (Table 1). Nevertheless,
the current results indicate that 3 μg of rlipoA-RBD
alone was enough to induce significant functional neu-
tralizing antibody levels against TcdA. Interestingly,
these anti-RBD IgG antibody responses had little or no
neutralization activity against TcdB (Table 1). Also, the
anti-RBD IgG antibody responses elicited by freeze-thaw
or heat-treated rlipoA-RBD were found to be significant
lower or have no neutralizing activity (data not shown).
Fig. 4 Cytokine secretion from BMDC treated with rlipoA-RBD. After BMDC was treated with rlipoA-RBD on day 6 for 18 h, the culture
supernatants were collected and analyzed for cytokine profiles using specific cytokine ELISA: (a) IL-6, (b) IL12p40, and (c) TNF- α. The experiments
had been performed at least three times
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Again, preserving the functionally active conformation of
rlipoA-RBD is vital to achieving neutralization activity.
To further evaluate the role of this anti-toxin neutral-
izing activity in vivo, mice were immunized 3 times
with increasing doses of rlipoA-RBD (0.3, 3, or 30 μg)
and challenged with 5 times the dose killing half of the
subjects (LD50) of TcdA. Low dose vaccination (0.3 μg)
induced a strong anti-RBD antibody response which
could neutralize TcdA in vitro Vero cell cytotoxicity
assay (neutralization titer 1/128) and fully protected
immunized mice against TcdA challenge. Our previous
study [30] indicated that 3 × 10 μg of A-rRBD was cap-
able of a >80 % protection rate in the TcdA mouse
challenge model, so to determine whether lower doses
could provide protection the challenge studies were
repeated with groups of mice (10 mice per group) vac-
cinated with either 3 × 0.3 or 3 × 3 μg of either
A-rRBD or rlipoA-RBD. The protection rates obtained
with 0.3 and 3 μg of A-rRBD were found to be 0 and
10 %, respectively (Fig. 7a). In contrast, the protection
rates obtained with 0.3 and 3 μg of rlipoA-RBD were 90
and 100 %, respectively (Fig. 7a). In another separate ex-
periment, mice (10 mice per group) were vaccinated with
3 × 0.3 or 3 × 3 μg of rlipoA-RBD, or with 3 × 30 μg of
B-rRBD, the protection rate was found to be 90 %, 100 %
and 0 % for 3 × 0.3 rlipoA-RBD, 3 × 3 μg and B-rRBD
groups, respectively (Fig. 7b). A low neutralizing antibody
titer (1/16) against TcdA was detected in mouse sera elic-
ited by 3 × 30 μg of B-rRBD, and these antibodies were
insufficient to protect mice from TcdA challenge in vivo.
Taken together, the results demonstrate that 3 × 0.3 μg of
rlipoA-RBD elicits neutralization titer >128 and provides
full protective immune responses in mice against C. diffi-
cile TcdA challenge, and strongly suggests rlipoA-RBD is a
good candidate for CDI vaccine developments.
Hamster challenge studies
To further evaluate the roles of anti-toxin neutralizing
antibodies in vivo, the C. difficile spore hamster chal-
lenge model was performed as described in the Materials
and Methods. Two groups of hamsters (n = 6) were
Fig. 5 Adjuvant effect of rlipoA-RBD. To demonstrate adjuvant effect
of rlipoA-RBD, the enhancement of anti-OVA IgG response was
evaluated by co-administration of rlipoA-RBD and OVA. BALB/c mice
were immunized with 3 × 2 μg of OVA formulated either with or
without various amounts of rlipoA-RBD (0.3 and 3 μg), 10 μg of
A-rRBD, or alum as positive control. Serum titer was determined by
RBD-specific ELISA
Fig. 6 Mouse anti-RBD antibody responses elicited by different dosages of A-rRBD or rlipoA-RBD. BALB/c mice were immunized three times with
either 3, 10 or 30 μg doses of A-rRBD; or with 3, 10 or 30 μg doses of rlipoA-RBD. Anti-RBD titers of mouse sera obtained at 0, 2, 4, 6, and 16 weeks
were determined by RBD-specific ELISA
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vaccinated 3 times with PBS 2 weeks apart (one group is
used for challenge as the positive control and one group
has no challenge as the negative control) and another
three separated groups of hamsters were immunized
with either 10 μg of A-rRBD, or 10 μg of rlipoA-RBD or
10 μg of B-rRBD intramuscularly. A week after the third
immunization, blood samples collected from immunized
hamster were assayed for anti-TcdA neutralizing antibdoy
titers and found to be <4, 8, 128 and 512 for PBS, B-rRBD,
A-rRBD and rlipoA-RBD groups, respectively (Table 1).
As shown in Table 1 only hamster antisera obtained from
the group immunized with B-rRBD had strong anti-TcdB
Table 1 Antibody responses of antisera obtained two weeks after 3 doses of different formulation of rlipoA-RBD in the mouse,
rabbit and hamster immunogenicity studies
Immunogenicity studies Anti-A-rRBD
IgG titer of pooled sera
Neutralization titer of pooled sera againsta
TcdA TcdB
Mouse A-rRBD (μg) 0 <100 <4 <4
3 3.5 × 103 32 <4
10 2.7 × 104 256 <4
30 5.3 × 104 128 <4
rlipoA-RBD (μg) 0.3 2.3 × 105 512 <4
3 2.3 × 105 512 <4
10 3.3 × 105 512 4
30 2.5 × 105 1024 4
TcdA toxoidb (μg) 10 7.7 × 104 256 <4
Rabbit A-rRBD (μg) 10 2.3 × 105 128 <4
rlipoA-RBD (μg) 10 7.7 × 105 512 <4
TcdA toxoidb (μg) 10 7.7 × 104 2048 <4
Hamster A-rRBD (μg) 10 3.7 × 104 128 <4
B-rRBD (μg) 10 2 × 103 8 64
rlipoA-RBD (μg) 10 5.7 × 105 512 8
A-rRBD (μg) + B-rRBDc (μg) 10 2.7 × 104 32 16
rlipoA-RBD (μg) + B-rRBD (μg) 10 7.7 × 105 512 64
A-rRBD (μg) + B-rRBD (μg) + alumc 10 4.3 × 105 64 64
A-rRBD (μg) + B-rRBD (μg) + Pam3CSK4d 10 1.7 × 105 32 8
aNeutralization titer of pooled sera against toxins was defined as the highest diluted sample which could protect against 50 % cell rounding induced by toxins
bMouse antibody responses to 3 doses of 10 μg of TcdA toxoid. The immunogenicity studies were performed and described in previous report [30]
cHamster antibody responses to 3 doses of 10 μg of each A-rRBD (μg) and B-rRBD formulated with 300 μg of alum
dHamster antibody responses to 3 doses of 10 μg of each A-rRBD (μg) and B-rRBD formulated with 10 μg of Pam3CSK4
Fig. 7 Mouse protection elicited by rlipoA-RBD against lethal TcdA challenge. Panel a, BALB/c mice (10 mice per group) were challenged with a
lethal dose of TcdA after three immunizations of either rlipoA-RBD or A-rRBD (0.3 and 3 ug). PBS served as the negative control. The final survival
rates were reported. Panel b, BALB/c mice (10 mice per group) were challenged with a lethal dose of TcdA after three immunizations of either
rlipoA-RBD (0.3 and 3 μg) or 30 μg of B-rRBD
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neutralizing antibody response (titer = 64). The hamster
anti-TcdA titers elicited by rlipoA-RBD were comparable
to those obtained from mice and rabbits. Two weeks after
the third immunization, hamsters were gastrically inocu-
lated with 100 CFU (the dose can kill >50 % of challenged
hamsters) of C. difficile. After 3 to 4 days 6/6, 6/6, 5/6 and
5/6 of hamsters died in the PBS, A-rRBD, rlipoA-RBD and
B-rRBD groups, respectively (data not shown). These re-
sults indicate that A-rRBD and B-rRBD alone could not
elicit protective immune responses in hamster challenge
model and are consistent with those results obtained from
previous studies [22, 31].
To test whether rlipoA-RBD formulated with B-rRBD
could provide protective immune responses in hamster
challenge model, groups of hamsters were immunized
with either PBS, 10 μg of A-rRBD, or 10 μg of rlipoA-RBD
with and without 10 μg of B-rRBD intramuscularly. A
week after the third immunization, blood samples col-
lected from immunized hamster were assayed for anti-
TcdA neutralizing antibdoy titers and found to be <4, 128
and 512 for PBS, A-rRBD and rlipoA-RBD + B-rRBD
groups, respectively (Table 1). As shown in Table 1 only
hamster antisera obtained from the group immunized
with rlipoA-RBD + B-rRBD had significant (p < 0.01)
anti-TcdB neutralizing antibody (titer = 64). Two weeks
after the third immunization, hamsters were gastrically
inoculated with 100 CFU of C. difficile (dose can
kill >50 % of challenged hamsters). After 3 to 4 days
3/6, 2/6, 2/6 and 0/6 of hamsters died in the PBS,
A-rRBD, rlipoA-RBD and rlipoA-RBD + B-rRBD
groups, respectively (Fig. 8a). Around 30 CFU of C. dif-
ficile were observed on selective TCCFA plates when
100 mg of the faecal pellets collected at day 12 from
the six surviving hamsters immunized with rlipoA-RBD +
B-rRBD were analyzed (Fig. 8b). In contrast, significant
amount (500 to 7,500 CFU of C. difficile (p < 0.01) were
found in the selective TCCFA plates when the faecal
pellets (100 mg) collected from other survived hamster
groups (Fig. 8b). It is clear that recombinant RBD derived
from either TcdA or TcdB individually was incapable of
providing total protection in the hamster challenge model
and these results are consistent with previous reports
[13, 17, 22, 31]. The current results indicate that rlipoA-
RBD formulated with B-rRBD could provide protection
that is similar to previous report that a fusion protein
containing A-rRBD/B-rRBD formulated in alum adjuvant
Fig. 8 C. difficile spore challenge in hamster model studies. Panel a, five groups of hamsters (n = 6) were gastrically inoculated with 100 CFU of
C. difficile (the dose can kill >50 % of hamsters) at 2 weeks after the third immunization with either PBS, A-rRBD, rlipoA-RBD, or rlipoA-RBD + B-rRBD.
The final survival rates were reported. Panel b, The number of C. difficile colonies (CFU) grown in TCCFA selective medium. Bacterial colonies
obtained from the faeces (~100 mg) of survived hamsters were determined every two days after challenge. The number of CFU shown in the
figure represented the geometric mean of CFU per 100 mg of feacal pellets obtained from survived hamsters in each group after the
spore challenge
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could elicit protective immune responses in hamster chal-
lenge model [22].
To test whether adjuvant would have an impact, the
hamster C. difficile spore challenge model was repeated
with groups of hamsters vaccinated 3 times either with
either PBS; 10 μg of rlipoA-RBD + 10 μg of B-rRBD; or
10 μg of A-rRBD + 10 μg of B-rRBD alone, or formu-
lated with either alum or Pam3CSK4. Pam3CSK4 is a
synthetic lipopeptide and is well recognized as a toll-like
receptor 2 agnoist [32]. Two weeks after the third
immunization, hamsters were gastrically inoculated with
100 CFU (the dose can kill >50 % of challenged hamsters)
of C. difficile. As shown in Fig. 9a, the survival rate was
found to be 1/6, 5/6, 3/6, 4/6 and 2/6 for PBS, rlipoA-
RBD + B-rRBD, A-rRBD + B-rRBD alone, and A-rRBD+
B-rRBD formulated with alum and Pam3CSK4 groups, re-
spectively. To correlate functional antibody responses with
in vivo protection, hamster sera were analyzed in Vero cell
cytotoxicity assay. Hamsters vaccinated with rlipoA-RBD
+ B-rRBD again had generated good anti-TcdA and TcdB
neutralizing antibody responses, the neutralization titers
were 512 and 64, respectively (Table 1). These good anti-
toxin antibody responses may correlate to better protec-
tion against a C. difficile spore challenge. Anti-toxin
neutralization titers found in the hamster group
vaccinated with A-rRBD+ B-rRBD formulated with
Pam3CSK4 was 32 and 8 against TcdA and TcdB, respect-
ively. This low neutralization titers indicate that Pam3CSK4
did not provide a strong adjuvant effect. Current results
also suggest that vaccine candidates containing 10 μg of
both A-rRBD +B-rRBD formulated with alum provides
partial protection (67 %).
The current studies have shown an interesting obser-
vation that a much less C. difficile colonized the selective
TCCFA plates when the faecal pellets collected from the
survived hamster groups vaccinated either with rlipoA-
RBD + B-rRBD or A-rRBD + B-rRBD formulated with
alum (Fig. 9b). These two groups have >60 % of survival
rate (Fig. 9a). Around 30 to 50 CFU per 100 mg of faecal
pellets were found in the selective TCCFA plates when
the faecal pellets collected from these two survived ham-
ster groups, but those obtained from other survived
hamster groups were found to be significant higher, 300
to 5,000 CFU per 100 mg of faecal pellet (p < 0.01). It
seems that the strong neutralizing antibody responses
not only provide better protection against the toxicity of
both toxins, but also help the host reduce the C. difficile
bacteria counts.
A-rRBD and B-rRBD alone or formulated with alum
did not provide full protection in the hamster challenge
Fig. 9 Adjuvant effect in hamster challenge model studies. Panel a, five groups of hamsters (n = 6) were gastrically inoculated with 100 CFU. of
C. difficile (the dose can kill >50 % of hamsters) at 2 weeks after the third immunization with either PBS, A-rRBD + B-rRBD, rlipoA-RBD + B-rRBD, or
A-rRBD + B-rRBD formulated with alum (300 μg) or Pam3CSK4 (10 μg). The final survival rates were reported. Panel b, The number of C. difficile
colonies (CFU) grown in TCCFA selective medium. Bacterial colonies obtained from the faeces (~100 mg) of survived hamsters were determined
every two days after challenge. The number of CFU shown in the figure represented the geometric mean of CFU per 100 mg of feacal pellets
obtained from survived hamsters in each group after the spore challenge
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model; these results strongly indicate that an efficacious
CDI vaccine requires the RBD from both TcdA and
TcdB. This is consistent with previous report by Tian
et al., [22] that a novel fusion protein containing the re-
ceptor binding domains of C. difficile toxin A and toxin
B (3 × 100 μg of fusion protein formulated with alum ad-
juvant) elicited protective immunity against lethal toxin
and spore challenge in preclinical efficacy models. Our
current vaccine formulation containing 10 μg of rlipoA-
RBD + 10 μg of B-rRBD consistently elicitstrong neutraliz-
ing antibody responses (Table 1) and protection (Fig 8a
and 9a) against C. difficile spore challenge in the hamster
model, and should be considered a strong vaccine candi-
date for CDI vaccine development and future clinical tri-
als. Although the current studies have indicated that
rlipoA-RBD can enhance immune responses through
its TLR-2 agonist activity (intrinsic adjuvant property),
further efforts are still required and should be pursued
to optimize vaccine efficacy, including hamster chal-
lenge study with other BI/NAP1/027 hyper-virulent
strains and a vaccination strategy for inducing rapid,
strong and long lasting protective immunity in elderly
and immuno-compromised individuals.
Conclusion
C. difficile vaccine development is urgently needed to
control the increasing incidence of hospital-acquired CDI
that are responsible for rising medical costs. Although
TcdA toxoid-based vaccines against CDI are currently in
phase III clinical trials, recombinant antigens as vaccine
candidates represent a new trend. Several studies have in-
dicated that the neutralizing antibodies elicited by active
immunization against clostridial toxins play very import-
ant roles in protection against infection and/or recurrence
of CDI [13], [17], [35]. The present study, we have devel-
oped a cost-effective and efficacious recombinant subunit
vaccine against CDI, using rlipoA-RBD as a rational design
to contain a toll-like receptor 2 agonist (intrinsic adjuvant
property) and achieved high yields in E. coli expression
system. The purified rlipoA-RBD was characterized
immunologically and found to have the following proper-
ties: (a) mice, hamsters and rabbits vaccinated with 3 μg of
rlipoA-RBD produced strong antibody responses that
could neutralize TcdA toxicity in the Vero cell cytotoxicity
assay and the neutralization titer was comparable to those
obtained from antisera immunized either with 10 μg of
TcdA toxoid or 30 μg of A-rRBD; (b) rlipoA-RBD elicited
immune responses and protected mice from TcdA
challenge, but insignificant protection (10 to 20 %) against
C. difficile spores challenge in the hamsters model; (c) only
rlipoA-RBD formulated with B-rRBD consistently confers
protection (90–100 %) in the hamsters challenge model;
and (d) rlipoA-RBD was found to be 10-fold more potent
than A-rRBD as an adjuvant to enhance immune
responses against poor antigens such as ovalbumin. These
results indicate that rlipoA-RBD formulated with B-rRBD
would be an excellent vaccine candidate for preclinical
studies and future clinical trials.
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